Feedback / Questions
rosopatamab-225Ac (CONV01-α) - Weill Cornell Medical College, Dominari Holdings
https://www.prnewswire.com/news-releases/convergent-therapeutics-announces-fda-clearance-of-ind-application-for-conv01--a-best-in-class-radioantibody-targeting-prostate-specific-membrane-antigen-302106271.html
Apr 2, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next